SNDL Inc.

NASDAQ:SNDL

Drug Manufacturers - Specialty & Generic

Healthcare
$1.34 -1.74%

-$0.03 today

Market cap
$326.64M
Beta
0.91
P/E (TTM)
-47.4
EPS (TTM)
-$0.04
52W Low $1.15High $2.89

Volume 1.00M

Average 2.21M

SNDL Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

SNDL Inc.NASDAQ: SNDL

Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares grows in line with its trailing trend

Q1 FY2026 weighted avg shares of 260.17M shares rose 0.4% year over year, ahead of the -1.2% change in trailing-twelve-month weighted avg shares. Sequentially, it fell 1.2% from the prior quarter. Over 3 fiscal years it compounded at +3.9% a year.

Context

  • Weighted avg shares increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +0.4% holds above the trailing-twelve-month pace of -1.2%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
260.17M-1.2% QoQ
Last fiscal yearDec 2025
258.05M-2.3% YoY
LTMMar 2026
259.55M-1.2% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+0.4%——
1 year-2.3%——
3-year CAGR+3.9%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
258.05M CAD
Year-over-year change
-2.3%
4-year CAGR
+8.5%

Weighted Avg Shares vs competitors

How SNDL compares with its peers on the latest reported figures

  • SNDL's LTM Mar 2026 weighted avg shares of 259.55M shares is the 2nd highest of the 11 companies compared; the peer median is 94.72M shares.
  • Its year-over-year change of -1.2% is the 10th highest of 11, against a peer median of +17.5%.
  • Over three fiscal years its annual growth of +3.9% compares with a peer median of +15.7%.
SNDL Competitors Peer median
Weighted Avg Shares for SNDL and competitors
Company Period LTM YoY 3-year CAGR
AKBAAkebia Therapeutics, Inc.LTM Mar 2026264.94M +21.2%+12.1%
SNDLSNDL Inc.LTM Mar 2026259.55M -1.2%+3.9%
ESPREsperion Therapeutics, Inc.LTM Mar 2026220.76M +13.9%+46.3%
ORGOOrganogenesis Holdings Inc.LTM Mar 2026127.11M -2.8%-0.9%
AQSTAquestive Therapeutics, Inc.LTM Mar 2026113.62M +23.3%+35.8%
CMPSCOMPASS Pathways plcLTM Mar 202698.1M +33.3%+30.1%
OLMAOlema Pharmaceuticals, Inc.LTM Mar 202691.34M +41.8%+29.6%
CRVSCorvus Pharmaceuticals, Inc.LTM Mar 202682.39M +23.5%+19.3%
SIGASIGA Technologies, Inc.LTM Mar 202671.58M +0.4%-0.6%
EOLSEvolus, Inc.LTM Mar 202664.73M +3.0%+4.8%
EBSEmergent BioSolutions Inc.LTM Mar 202652.93M -1.2%+2.2%
Peer median (excluding SNDL) 94.72M+17.5%+15.7%

Competitors are the stored peer set for SNDL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

CAD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue56.13M712.2M909.01M920.45M946.4M
Cost of Revenue65.13M571.82M718.59M680.12M687.75M
Gross Profit(9M)140.38M190.42M240.33M258.65M
Gross Margin-16.0%19.7%20.9%26.1%27.3%
Research & Development2.45M2.45M324K346K489K
Selling, General & Admin55.39M158.26M230.17M219.28M210.63M
Operating Expenses125.38M488.15M353.59M344.14M263.07M
Depreciation & Amortization10.16M47.32M64.95M56.71M56.27M
EBITDA(223.76M)(326.55M)(99.15M)(41.2M)48.02M
EBITDA Margin-398.7%-45.9%-10.9%-4.5%5.1%
Operating Income(134.38M)(347.77M)(163.17M)(103.81M)(4.42M)
Operating Margin-239.4%-48.8%-18.0%-11.3%-0.5%
Interest Income13.72M17.62M15.37M16.4M8.05M
Interest Expense776K5.9M7.92M7.7M7.52M
Other Income / Expenses(100.32M)(32M)(8.85M)(1.8M)(11.35M)
Income Before Tax(234.7M)(379.77M)(172.02M)(105.61M)(15.77M)
Pre-Tax Margin-418.1%-53.3%-18.9%-11.5%-1.7%
Income Tax Expense(7.91M)(7.34M)0(9.41M)0
Net Income(226.98M)(335.11M)(172.66M)(94.8M)(15.77M)
Net Margin-404.4%-47.1%-19.0%-10.3%-1.7%
EPS (Basic)(1.24)(1.50)(0.65)(0.38)(0.06)
EPS (Diluted)(1.24)(1.50)(0.65)(0.38)(0.06)
Weighted Avg Shares186.04M229.87M259.37M264.2M258.05M
Weighted Avg Shares (Diluted)186.04M229.87M259.37M264.2M258.05M

SNDL Inc.

NASDAQ:SNDL

Intrinsic Alpha fair value

Locked

Current Price

$1.34

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.